Affiliations: [a] Department of Molecular Biology, Centocor, Malvern, PA, USA | [b] Department of Biopharmaceutical R&D, Centocor, Malvern, PA, USA
Note: [] Address reprint requests to Dr. David M. Knight, Department of Molecular Biology, Centocor, 200 Great Valley Parkway, Malvern, PA 19355, USA.
Abstract: Human monoclonal antibodies (MAbs) offer potential advantages over murine MAbs for therapy because they are not likely to elicit immune responses and are expected to interact more efficiently with the human immune system to activate therapeutically useful functions. Traditional methods for obtaining human MAbs (i.e., immortalization of B cells by cell fusion or transformation) can result in low and unstable antibody secretion. Recently, methods have been devised for direct cloning of human variable region genes via polymerase chain reaction and phage combinatorial libraries. Both types of human MAb production can benefit from expression systems that support the stable, high-level antibody secretion required for therapeutic use. Using an existing human-derived hybridoma that secretes a human IgM antibody as a convenient source of antibody genes, we have demonstrated that cloned human antibody genes can be efficiently expressed in murine myeloma cells and that cell lines with properties suitable for large-scale economical production can be obtained. We were unable to detect any differences between the antibodies produced by the original hybridoma and the engineered cell line. In addition, we were able to express an IgG form of the antibody, showing that expression of a recombinant human antibody need not be limited to the original antibody class.
Keywords: antibody gene expression, recombinant antibodies, human antibodies
